The present invention relates to a collagen sponge-type composition for bone regeneration characterized in that the composition is manufactured by homogenizing a hydrated collagen; and a mixed solution of the lidocaine, epinephrine and thrombin, and then lyophilizing same. The composition according to the present invention, which activates undifferentiated cells in bone marrow and also activates bone regeneration capacity in bone marrow through the activation and differentiation of osteoclasts and osteoblasts, may be a method for successful treatment of medication-related osteonecrosis of the jaw (MRONJ) through a bone marrow activation treatment method, and may develop the treatment of the fundamental causes of MRONJ through a bone marrow activation treatment method using various growth factors for bone marrow activation and bone marrow activation factors such as cytokines and completely regenerate jaw bone conditions aesthetically and functionally. Accordingly, the composition according to the present invention may be useful in the treatment of various diseases caused by bone remodeling failure.

Embodiments herein described provide antigen-presenting cell-mimetic scaffolds (APC-MS) and use of such scaffolds to manipulating T-cells. More specifically, the scaffolds are useful for promoting growth, division, differentiation, expansion, proliferation, activity, viability, exhaustion, anergy, quiescence, apoptosis, or death of T-cells in various settings, e.g., in vitro, ex vivo, or in vivo. Embodiments described herein further relate to pharmaceutical compositions, kits, and packages containing such scaffolds. Additional embodiments relate to methods for making the scaffolds, compositions, and kits/packages. Also described herein are methods for using the scaffolds, compositions, and/or kits in the diagnosis or therapy of diseases such as cancers, immunodeficiency disorders, and/or autoimmune disorders.

The present disclosure relates to a method of imaging, involving administration of a bi-phasic formulation followed by application of high frequency sound waves to identify a region of interest. Following identification, a phase shift of the bi-phasic formulation may be activated by a second administration of high frequency sound waves such that gaseous components of the bi-phasic formulation are enlarged and localised at the region of interest.

In various embodiments, a tissue thickness compensator can comprise one or more capsules and/or pockets comprising at least one medicament therein. In at least one embodiment, staples can be fired through the tissue thickness compensator to rupture the capsules. In certain embodiments, a firing member, or knife, can be advanced through the tissue thickness compensator to rupture the capsules.

An osteogenic composition suitable for use in bone and soft tissue reparative procedures is provided for herein. Methods for preparing osteogenic composition from blood and bone marrow are also provided for. The osteogenic compositions contain therapeutically effective concentrations of one or more osteogenic agents such as BMP-2, TGF-β, PDGF and VEGF.

The present invention is related to a biofunctional three-dimensional hydrogel suitable for the expansion of freshly isolated or frozen intestinal cells and the formation of intestinal organoids therefrom, that avoids the use of a naturally-derived matrix such as Matrigel and provides intestinal organoids suitable for clinical applications and generated in a commercially feasible manner. The present invention is also related to a kit of parts comprising said hydrogel in combination with a suitable culture medium, and to a method of making organoids and expanding cells from freshly isolated or frozen intestinal cells with said kit of parts.

The polymer film serves for the embedding of a medical technology product to be implanted in a human organism. The polymer film includes a polymer of natural origin being biodegradable and absorbable by the human body. The polymer film has a polymer content. The polymer film further includes two antimicrobial active ingredients having a different mechanism of action and the polymer film has a total active-ingredient content. The ratio of the total active-ingredient content to the polymer content is at least 15%. The polymer content is greater than the total active-ingredient content. The polymer film is bendable and modulable and uninterrupted. The polymer forms a polymer matrix in which the antimicrobial active ingredients are embedded in a homogeneously distributed manner. The polymer film has, for each of the antimicrobial active ingredients, an individual active-ingredient content deviating from one another by at most 20%.

A dressing device and a method of making the dressing device is disclosed. For example, the method can include forming a polyurethane foam, adhering a moisture vapor-transmissive backing to the polyurethane foam, and cutting the polyurethane foam with the moisture vapor-transmissive backing thereon to form the dressing device. Notably, forming the polyurethane foam can include mixing together a polyurethane prepolymer and an aqueous mixture of chlorhexidine di-gluconate and polyanhydroglucuronic acid or a salt of polyanhydroglucuronic acid in a first reaction vessel until a homogenous mixture is formed; dispensing the homogenous mixture onto a liner; and allowing the homogeneous mixture to expel carbon dioxide. Upon expelling the carbon dioxide, the polyurethane foam is formed with the chlorhexidine di-gluconate and the polyanhydroglucuronic acid or the salt of polyanhydroglucuronic acid homogenously dispersed throughout the polyurethane foam.

Methods are disclosed for the reduction or elimination of bacterial biofilms on biological and non-biological surfaces, as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms using compositions comprising a synergistic combination of thermolysin and at least one aminoglycoside antibacterial agent.

Dressings, systems, and methods for treating a tissue site are described herein. The dressing has a contact layer having a plurality of holes. The contact layer is configured to be positioned adjacent to the tissue site. The dressing also includes a cover layer having a first side configured to be positioned adjacent to the contact layer and a second side opposite the first side. An antimicrobial agent is coupled to the first side of the cover layer. The dressing has a drape configured to be positioned over the cover layer to form a sealed space having the contact layer and the cover layer disposed in the sealed space.